Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Multiple sclerosis in 2010

Advances in monitoring and treatment of multiple sclerosis

Nature Reviews Neurology volume 7, pages 74–75 (2011)Cite this article

Subjects

2010 represented a milestone in the history of multiple sclerosis monitoring and treatment. MRI and immunological biomarkers were identified to track disease evolution and, ultimately, to guide treatment decisions. Moreover, oral disease-modifying therapies emerged that should increase treatment regimen adherence and improve patient outcomes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol. 58, 840–846 (2005).

    Article  PubMed Central  Google Scholar 

  2. Doggrell, S. A. Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group. Expert Opin. Pharmacother. 11, 1225–1230 (2010).

    Article  CAS  Google Scholar 

  3. McDonald, W. I. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50, 121–127 (2001).

    Article  CAS  Google Scholar 

  4. Montalban, X. et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 74, 427–434 (2010).

    Article  CAS  PubMed Central  Google Scholar 

  5. Ingram, G. et al. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133, 1602–1611 (2010).

    Article  PubMed Central  Google Scholar 

  6. Goodin, D. S. et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 68, 977–984 (2007).

    Article  CAS  PubMed Central  Google Scholar 

  7. van der Voort, L. F. et al. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. Arch. Neurol. 67, 402–407 (2010).

    Article  PubMed Central  Google Scholar 

  8. Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387–401 (2010).

    Article  CAS  Google Scholar 

  9. Giovannoni, G. et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362, 416–426 (2010).

    Article  CAS  Google Scholar 

  10. Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402–415 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neuroscience, Neuroimaging Research Unit, Institute of Experimental Neurology, Scientific Institute and University Hospital San Raffaele, via Olgettina 60, 20132, Milan, Italy

    Massimo Filippi

Authors
  1. Massimo Filippi
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

M. Filippi has acted as a consultant and a speaker for Bayer-Schering Pharma, Biogen Dompé, Genmab A/S, Merck Serono and Teva Pharmaceutical Industries. He has also received research support from these companies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Filippi, M. Advances in monitoring and treatment of multiple sclerosis. Nat Rev Neurol 7, 74–75 (2011). https://doi.org/10.1038/nrneurol.2010.215

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneurol.2010.215

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research